37LOW

ALA

AROVELLA FPO [ALA]
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Healthcare · ASX Small Cap
$0.0690 +3.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical44
Catalyst53
Sentiment50
Fundamental57
Momentum62
Risk Gate46
Get alerts when ALA's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track ALA — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Strong cash runway (11 quarters)
  • Near 52-week low (5% of range)
  • Small-cap ($20-100M)
  • Capital raise activity (1 events)
  • CANSLIM I: Institutional ownership (12%)
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.48%/day)
  • Altman Z-Score grey zone (1.85, low-confidence approx)
  • Beneish M-Score 4.12 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Revenue declining (-7%)
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-247%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about ALA
"What's driving ALA's score?" "How does ALA compare to peers?" "Key risks for ALA?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE TGA Clears ALA-101 Trial Under CTN Scheme
NONE Half Year Report and Appendix 4D
NONE 20260219 ALA 708A Cleansing Notice
Announcement tone +3pts

Recent ASX Announcements

2026-03-15 TGA Clears ALA-101 Trial Under CTN Scheme
2026-02-19 Half Year Report and Appendix 4D PRICE SENSITIVE
2026-02-18 20260219 ALA 708A Cleansing Notice
2026-02-18 Notification of cessation of securities - ALA
2026-02-18 Application for quotation of securities - ALA

Key Metrics

$85.7M
Market Cap
597K
Avg Volume
1.4x
Vol Ratio
$0.07 — $0.12
52-Week Range
0.1%
Short Interest
N/A
Cash Runway
-52.0%
ROE
-246.9%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 75%
LLeader vs LaggardlaggardRS: -6
IInstitutional SponsorshippassInst: 12%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #106 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:ALA vs ATXALA vs PNVALA vs IMM
Scout Pro — Deeper Analysis for ALA
Try Pro free for 30 days
Share this analysis

Track ALA and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required